This page shows the latest Disarm Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Deal could eventually be worth up to $1.36bn. Eli Lilly is set to acquire private biotech company Disarm Therapeutics for an initial upfront payment of $135m, with a focus on ... Disarm’s focus is on the development of a new class of disease-modifying
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...